Allogene outlines cash runway into Q1 2029 while raising...

2026-05-14 07:51:48 ET More on Allogene Therapeutics Allogene Therapeutics, Inc. (ALLO) Q1 2026 Earnings Call Transcript Allogene Therapeutics, Inc. (ALLO) Discusses Interim Futility Analysis from Pivotal Phase II ALPHA 3 Trial in First-Line Consolidation Large B-Cell Lymphoma - Slideshow Allogene Therapeutics, Inc. (ALLO) Discusses Interim Futility Analysis from Pivotal Phase II ALPHA 3 Trial in First-Line Consolidation Large B-Cell Lymphoma Transcript Allogene Therapeutics GAAP EPS of -$0.18 beats by $0.01 Allogene Therapeutics Q1 2026 Earnings Preview Read the full article on Seeking Alpha For further details see: Allogene outlines cash runway into Q1 2029 while raising 2026 operating cash expense guidance to ~$165M